Clene Inc.

Analysis for Ticker: CLNN

Clene Inc is a biotechnology company that claims to treat neurodegenerative diseases like amyotrophic lateral sclerosis and multiple sclerosis using gold nanocrystals, but the current math reveals a desperate corporate machine designed to harvest investor cash rather than cure patients. As of 04/05/2026, the company is attempting to distract the market with a government meeting about using surrogate biomarkers to get their drug approved faster, despite the agency having rejected this pathway once before. The share price is 7,08$ and the market cap sits between 72,3$ million and 83,6$ million, but the numbers are a disaster. The company is nearly out of money and is surviving on a monthly allowance from a university grant that can be canceled with a thirty-day notice. To move forward, they must start an expensive and massive new clinical study in early 2027 that they simply cannot afford. This is a business with no revenue and a mountain of compounding debt that is already larger than the actual value of the company.